Internal Medicine, Hematology & Oncology · Flemington, NJ
NPI
1750546610
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
2100 Wescott Dr
Flemington, NJ, 08822
Phone (908) 788-6461
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.7M
281,346 services
Medicare patients, 2024
616
Average age 75
Drug cost, 2024
$8.2M
1,398 prescriptions
Company payments, 2025
$2,359
From 41 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Waqas Rehman was code J1439 (injection, ferric carboxymaltose, 1 mg), 79,510 times for 58 patients. In total Waqas Rehman billed 281,346 services in 167 codes, and Medicare paid $3.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-12-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 79,510 | 58 | $0.87 | $69K |
| J9299 Injection, nivolumab, 1 mg | Office | 14,520 | 11 | $24.60 | $357K |
| J0897 Injection, denosumab, 1 mg | Office | 11,043 | 88 | $20.54 | $227K |
| J0185 Injection, aprepitant, 1 mg | Office | 10,660 | 32 | $1.34 | $14K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 10,290 | 16 | $8.59 | $88K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 8,712 | 31 | $21.48 | $187K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 7,084 | 43 | $6.31 | $45K |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 6,200 | 26 | $4.39 | $27K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,969 | 50 | $0.09 | $179 |
| 85025 Blood Count | Office | 1,609 | 400 | $7.61 | $12K |
| J2796 Injection, romiplostim, 10 micrograms | Office | 1,504 | 11 | $78.15 | $118K |
| 96372 Injection Administration | Office | 933 | 218 | $12.50 | $12K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 784 | 17 | $0.07 | $58.37 |
| 99213 Office E&M - Established | Office | 751 | 345 | $72.67 | $55K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 660 | 17 | $0.75 | $498 |
By year: 2022 $3.9M for 265,587 services; 2023 $3.2M for 256,056 services; 2024 $3.7M for 281,346 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,609 | 400 | $7.61 | $12K |
| 80053 Clinical Chemistry | 464 | 207 | $10.35 | $4,802 |
| 83615 Clinical Chemistry | 452 | 203 | $5.92 | $2,676 |
| 83735 Clinical Chemistry | 356 | 154 | $6.57 | $2,339 |
| 84100 Clinical Chemistry | 354 | 154 | $4.65 | $1,646 |
| 36415 Venipuncture Blood Collection | 329 | 213 | $8.65 | $2,846 |
| 84439 Clinical Chemistry | 58 | 33 | $8.84 | $513 |
| 84443 Clinical Chemistry | 58 | 33 | $16.46 | $955 |
| 82378 Clinical Chemistry | 48 | 34 | $18.58 | $892 |
| 82306 Clinical Chemistry | 39 | 32 | $29.01 | $1,131 |
Medicare prescription drug claims, 2024
In 2024, the drug Waqas Rehman prescribed most often to Medicare patients was Procrit (Epoetin Alfa), with 82 prescriptions and refills. In total Waqas Rehman wrote 1,398 Medicare prescriptions that cost $8.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Procrit Epoetin Alfa | 82 | 82 | 31 | $299K |
| Anastrozole Generic | 61 | 146 | 18 | $1,239 |
| Hydroxyurea Generic | 56 | 79 | Under 11 | $1,326 |
| Eliquis Apixaban | 56 | 70 | Under 11 | $41K |
| Ninlaro Ixazomib Citrate | 54 | 54 | Under 11 | $677K |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 46 | 46 | Under 11 | $533K |
| Neulasta Pegfilgrastim | 45 | 45 | Under 11 | $358K |
| Prednisone Generic | 39 | 47 | 19 | $237 |
| Mvasi Bevacizumab-Awwb | 37 | 37 | Under 11 | $242K |
| Erleada Apalutamide | 34 | 44 | Under 11 | $627K |
| Revlimid Lenalidomide | 34 | 34 | Under 11 | $688K |
| Xtandi Enzalutamide | 33 | 33 | Under 11 | $456K |
| Neulasta Onpro Pegfilgrastim | 32 | 32 | Under 11 | $203K |
| Jakafi Ruxolitinib Phosphate | 32 | 32 | Under 11 | $550K |
| Acyclovir Generic | 32 | 46 | Under 11 | $207 |
Brand drugs: 852 claims; generic drugs: 546 claims; opioid claims: 27.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Waqas Rehman $2,359 ($2,359 in general payments such as food, travel and fees) from 41 companies. The largest payer was Novartis Pharmaceuticals Corporation with $707.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 14 | $707 |
| Daiichi Sankyo Inc. 4568.T | 7 | $149 |
| AstraZeneca Pharmaceuticals LP AZN | 7 | $137 |
| Pfizer Inc. PFE | 5 | $118 |
| Genzyme Corporation SNY | 5 | $101 |
| Gilead Sciences, Inc. GILD | 5 | $89.08 |
| E.R. Squibb & Sons, L.L.C. BMY | 5 | $86.14 |
| GlaxoSmithKline, LLC. GSK | 4 | $78.84 |
| Janssen Biotech, Inc. JNJ | 4 | $76.21 |
| Abbvie Inc. ABBV | 4 | $69.7 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.